ProfileGDS5678 / 1426743_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 86% 85% 85% 88% 87% 90% 88% 89% 89% 89% 89% 87% 86% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.8056788
GSM967853U87-EV human glioblastoma xenograft - Control 26.5600986
GSM967854U87-EV human glioblastoma xenograft - Control 36.3767285
GSM967855U87-EV human glioblastoma xenograft - Control 46.47885
GSM967856U87-EV human glioblastoma xenograft - Control 56.9497888
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.4723387
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.9934190
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.8343688
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.9630989
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.9832289
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.9104589
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.1056589
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.6403687
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.5072486